Embryonic Stem Cell News and Research

RSS

Endothelial cells can produce copious amounts of adult stem cells: Study

In a leap toward making stem cell therapy widely available, researchers at the Ansary Stem Cell Institute at Weill Cornell Medical College have discovered that endothelial cells, the most basic building blocks of the vascular system, produce growth factors that can grow copious amounts of adult stem cells and their progeny over the course of weeks.

5 Mar 2010

Evaluating bone defect repairs using human stem cells: NeoStem, University of Michigan enter into SRA

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it has entered into a sponsored research agreement (SRA) with the University of Michigan to evaluate bone defect repairs using human stem cells. The one-year project, beginning in March, will be funded through the proceeds of a $108,746 grant from the National Institutes of Health (NIH) under the Small Business Innovative Research Program (SBIR).

4 Mar 2010

Corning commercializes new Synthemax synthetic surface for supporting growth and differentiation of stem cells

Corning Incorporated today introduced the Corning® Synthemax™ surface, a novel synthetic surface that supports the growth and differentiation of stem cells. The surface is being commercialized as a result of Corning’s ongoing collaboration with Geron Corporation. This development enables researchers to take the next step toward scalable and cost-effective manufacturing of stem cells for potential therapies in the treatment of degenerative diseases.

4 Mar 2010

"Stem cells in drug discovery and development" workshop to be held during toxicology annual meeting

Cellular Dynamics International (CDI) and Hoffmann-La Roche Inc. (Roche) today announced a workshop to be held during the Society of Toxicology Annual Meeting in Salt Lake City, UT, on March 7 - 11.

3 Mar 2010

Axiogenesis, Lonza Cologne announce global distribution agreement

Axiogenesis AG has entered into a worldwide, exclusive distribution agreement with Lonza Cologne AG effective 01 January 2010. The agreement includes Axiogenesis’s current product and service portfolio, including the industry standard Cor.At® mouse embryonic stem cell-derived cardiomyocytes.

3 Mar 2010

Pioneering stem cell research could revolutionize treatments for diabetes and Alzheimer's disease

A heart patient's own skin cells soon could be used to repair damaged cardiac tissue thanks to pioneering stem cell research of the University of Houston's newest biomedical scientist, Robert Schwartz.

3 Mar 2010

Advanced Cell Technology’s MA09-hRPE cells for treatment of SMD: FDA grants orphan drug designation

Advanced Cell Technology, Inc., a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company’s MA09-hRPE cells for use in the treatment of Stargardt’s Macular Dystrophy (SMD). As a result, the company is eligible to receive a number of benefits, including tax credits, access to grant funding for clinical trials, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of as long as seven years.

3 Mar 2010

Fate Therapeutics named to Technology Review's 2010 TR50 most innovative companies in the world list

Fate Therapeutics, Inc. announced today that the Company was named as one of Technology Review's 2010 TR50, the publication's first annual list of the 50 most innovative companies in the world. The 2010 TR50 companies span the fields of energy, computing, the Web, biomedicine, and materials and have been evaluated based on business model, strategies for deploying and scaling up its technologies and the likelihood of success. Each company in the 2010 TR50 has excelled not only at inventing technology but also at using it to transform how we live and work.

26 Feb 2010

Retinitis Pigmentosa: Embryonic stem cells for replacement of diseased retinal cells and restoration of sight

An international research team led by Columbia University Medical Center successfully used mouse embryonic stem cells to replace diseased retinal cells and restore sight in a mouse model of retinitis pigmentosa. This strategy could potentially become a new treatment for retinitis pigmentosa, a leading cause of blindness that affects approximately one in 3,000 to 4,000 people, or 1.5 million people worldwide.

25 Feb 2010

U.S. government's decision helped stem-cell researchers concentrate on science, but limitations remain

The United States government's decision last year to lift restrictions on federally-funded stem cell research has helped the nation's stem-cell researchers concentrate on science, but limitations remain - even under the new policy, according to George Daley, a Howard Hughes Medical Institute investigator at Children's Hospital Boston.

22 Feb 2010

Simple molecular kit to reprogram any cell of the body into another

In an effort to sidestep the ethical dilemma involved in using human embryonic stem cells to treat diseases, scientists are developing non-controversial alternatives: In particular, they are looking for drug-like chemical compounds that can transform adult skin cells into the stem cells now obtained from human embryos. That's the topic of a fascinating article in Chemical & Engineering News (C&EN), ACS' weekly newsmagazine.

19 Feb 2010

UCSF team: NIH ethics guidelines for embryonic stem cell research need to be modified

A UCSF team, led by bioethicist Bernard Lo, MD, recommends that the National Institutes of Health ethics guidelines for embryonic stem cell research be modified to better protect the rights of individuals donating egg or sperm to patients undergoing in vitro fertilization.

19 Feb 2010

Athersys completes enrollment in phase I MultiStem allogeneic stem cell therapy clinical trial

Athersys, Inc. and Angiotech Pharmaceuticals, Inc. announced that Athersys has completed patient enrollment for its phase I clinical trial of MultiStem(R), its allogeneic stem cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. Top line results of the trial are expected to be announced midyear, upon completion of the four-month patient follow-up visits and analysis of results.

17 Feb 2010

ACT's research on therapeutic cell types obtained from iPS cells featured in leading news media outlets

Advanced Cell Technology or “ACT” announced today that its research involving therapeutic cell types obtained from induced pluripotent stem (iPS) cells has been featured in several leading news media outlets: Scientific American, USA Today and Newsweek.

17 Feb 2010

International Stem Cell's human cornea technology: Clinical-commercial opportunities in Asia and Europe

International Stem Cell Corporation, announced today that multiple international meetings taking place between ISCO’s executive management and researchers and clinicians from commercial entities in both Asia and Europe revealed significant clinical-commercial opportunities for the company’s stem cell-derived human cornea technology in those regions.

17 Feb 2010

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

The new decade may herald an era of cell therapy -- treating human diseases by delivering highly specific beneficial cells. In the wake of an NIH decision late last year permitting federally funded researchers to use new lines of human embryonic stem cells, the door has opened more widely to stem cell research.

16 Feb 2010

Transition through hemogenic endothelial intermediate necessary for hematopoietic stem cell formation

Biologists at UC San Diego have identified the specific region in vertebrates where adult blood stem cells arise during embryonic development.

14 Feb 2010

Therapeutic cell types obtained from iPS cells demonstrate abnormal expansion and early cellular aging

Advanced Cell Technology, Inc. or “ACT” reported that a range of therapeutic cell types obtained from induced pluripotent stem (iPS) cells exhibit abnormal expansion and early cellular aging. The research, which appears online (published-ahead-of- print) in the journal STEM CELLS by ACT and its collaborators at Stem International (SCRMI), Harvard Medical School, and the University of Illinois, compares a variety of replacement cell types derived from human iPS cells with their embryonic stem (ES) cell counterparts. The findings support the use of ACT’s single blastomere-derived human embryonic stem cell lines which do not display early aging.

12 Feb 2010

hESC and iPSC: Long-term stem cell evaluation and comparison study

For the first time, scientists have performed a detailed long-term evaluation and comparison of two different types of pluripotent stem cells: human embryonic stem cells (hESC) and induced pluripotency stem cells (iPSC). Both cell types are believed to share equal characteristics, abilities and potential to differentiate into nearly 220 different cell types. However, hESC are isolated from early human embryos and iPSC are derived from reprogrammed adult somatic cells which makes them less controversial.

11 Feb 2010

Therapeutic cell types obtained from iPS cells exhibit abnormal expansion and early cellular aging

Advanced Cell Technology, Inc. reported that a range of therapeutic cell types obtained from induced pluripotent stem (iPS) cells exhibit abnormal expansion and early cellular aging.

11 Feb 2010

Embryonic Stem Cell News and Research

Endothelial cells can produce copious amounts of adult stem cells: Study

Evaluating bone defect repairs using human stem cells: NeoStem, University of Michigan enter into SRA

Corning commercializes new Synthemax synthetic surface for supporting growth and differentiation of stem cells

"Stem cells in drug discovery and development" workshop to be held during toxicology annual meeting

Axiogenesis, Lonza Cologne announce global distribution agreement

Pioneering stem cell research could revolutionize treatments for diabetes and Alzheimer's disease

Advanced Cell Technology’s MA09-hRPE cells for treatment of SMD: FDA grants orphan drug designation

Fate Therapeutics named to Technology Review's 2010 TR50 most innovative companies in the world list

Retinitis Pigmentosa: Embryonic stem cells for replacement of diseased retinal cells and restoration of sight

U.S. government's decision helped stem-cell researchers concentrate on science, but limitations remain

Simple molecular kit to reprogram any cell of the body into another

UCSF team: NIH ethics guidelines for embryonic stem cell research need to be modified

Athersys completes enrollment in phase I MultiStem allogeneic stem cell therapy clinical trial

ACT's research on therapeutic cell types obtained from iPS cells featured in leading news media outlets

International Stem Cell's human cornea technology: Clinical-commercial opportunities in Asia and Europe

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

Transition through hemogenic endothelial intermediate necessary for hematopoietic stem cell formation

Therapeutic cell types obtained from iPS cells demonstrate abnormal expansion and early cellular aging

hESC and iPSC: Long-term stem cell evaluation and comparison study

Therapeutic cell types obtained from iPS cells exhibit abnormal expansion and early cellular aging

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News